Sydney, Australia 28 February 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is delighted to announce that Dr Robert Miller will be working part-time as Consultant Chief Medical Officer.
Dr Miller joined the pharmaceutical industry in 1988 and is a Managing Partner in Artemida Pharma Limited a drug development consultancy providing strategic expertise. Dr Miller has provided medical management and clinical development support for both small and large pharmaceutical and biotechnology companies over his 30-year career in the industry including those specialising in radiopharmaceuticals.
Dr Miller is a fellow of the Royal College of Surgeons, Faculty of Pharmaceutical Medicine and the Royal Society of Medicine. He is also a member of the European Society of Medical Oncologists and affiliate member of the American Society of Clinical Oncologists. He received his medical training at The London Hospital Medical College and held a number of surgical and medical appointments across various hospitals in the UK.
Dr Miller commented on his appointment: “I am pleased to work with Clarity as their Consultant Chief Medical Officer at this important stage when the Company is actively progressing its clinical pipeline. I believe that my extensive experience as a Chief Medical Officer and Medical Adviser for a number of biotechnology companies with similar products in the pipeline will aid Clarity’s efforts of advancing its product development for a number of diagnostic and therapeutic indications. I see a lot of potential in Clarity’s theranostic technology and am looking forward to working together with the Team to improve treatment outcomes for patients with cancer and other serious diseases.”
Clarity’s Executive Chairman, Dr Alan Taylor commented: “We are honoured to have Dr Robert Miller as our Consultant Chief Medical Officer at this crucial stage of Clarity’s development, as he not only has a strong background in oncology as well as in the radiopharmaceutical arena, but he also brings his substantial medical expertise and strategic planning experience to Clarity. Dr Miller’s in-depth knowledge of protocol development, particularly in early phase studies, and his frequent input in medical affairs to support health authority applications and interactions, will be invaluable in taking Clarity to the next phase of clinical development.”
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
